Literature DB >> 22137704

Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy.

Firas Abdollah1, Jan Schmitges, Maxine Sun, Rodolphe Thuret, Orchidee Djahangirian, Zhe Tian, Shahrokh F Shariat, Alberto Briganti, Paul Perrotte, Francesco Montorsi, Pierre I Karakiewicz.   

Abstract

OBJECTIVE: A formal validation and head-to-head comparison of the National Comprehensive Cancer Network (NCCN) practice guideline lymph node invasion (LNI) nomogram, Partin tables, and D'Amico risk-classification was conducted for prediction of LNI at radical prostatectomy (RP).
METHODS: We focused on 20,877 patients treated with RP and pelvic lymph node dissection (PLND) between 2004 and 2006 within the Surveillance, Epidemiology and End Results database. The discrimination of the 3 tools in predicting histologically confirmed LNI was quantified using the area under the curve (AUC). Calibration plots were used to graphically depict the performance characteristics of the examined tools. In addition, we relied on decision curve analyses to compare the 3 models directly in a head-to-head fashion.
RESULTS: Overall, 2.5% of patients had LNI. The NCCN LNI nomogram (AUC 82%) outperformed the Partin tables (73%) and the D'Amico risk-classification (75%) for prediction of LNI. Calibration plots revealed that all 3 tools overestimated the risk of LNI. Partin tables showed the highest net-benefit for probability threshold range between 1% and 4%. Conversely, the NCCN LNI nomogram showed the highest net-benefit for the remaining threshold probabilities.
CONCLUSION: The NCCN LNI nomogram had the highest discrimination accuracy. However, using the decision curve analysis, the Partin tables demonstrated the highest net benefit when a threshold probability of LNI is <4%. In contrast, the NCCN LNI nomogram had the highest net benefit when the threshold probability used to perform PLND is greater than 4%. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137704     DOI: 10.1016/j.urology.2011.07.1423

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Authors:  Hillary M Ross; Oleksandr N Kryvenko; Janet E Cowan; Jeffry P Simko; Thomas M Wheeler; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

2.  Re-evaluating the concept of "dominant/index tumor nodule" in multifocal prostate cancer.

Authors:  Cheng Cheng Huang; Fang-Ming Deng; Max X Kong; Qinhu Ren; Jonathan Melamed; Ming Zhou
Journal:  Virchows Arch       Date:  2014-03-12       Impact factor: 4.064

3.  Comparison of nomograms predicting lymph node invasion in patients undergoing radical prostatectomy for prostate cancer.

Authors:  G J Nason; E M O'Connor; D MacMahon; B Moss; S W Considine; A Cahill; C O'Rourke; F M O'Brien
Journal:  Ir J Med Sci       Date:  2017-05-06       Impact factor: 1.568

4.  An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.

Authors:  John B Eifler; Zhaoyang Feng; Brian M Lin; Michael T Partin; Elizabeth B Humphreys; Misop Han; Jonathan I Epstein; Patrick C Walsh; Bruce J Trock; Alan W Partin
Journal:  BJU Int       Date:  2012-07-26       Impact factor: 5.588

Review 5.  From past to future: Bibliometric analysis of global research productivity on nomogram (2000-2021).

Authors:  Xiaoxue Wang; Jingliang Lu; Zixuan Song; Yangzi Zhou; Tong Liu; Dandan Zhang
Journal:  Front Public Health       Date:  2022-09-20

6.  Predictive efficacy of the 2014 International Society of Urological Pathology Gleason grading system in initially diagnosed metastatic prostate cancer.

Authors:  Guang-Xi Sun; Peng-Fei Shen; Xing-Ming Zhang; Jing Gong; Hao-Jun Gui; Kun-Peng Shu; Jiang-Dong Liu; Jinge Zhao; Yao-Jing Yang; Xue-Qin Chen; Ni Chen; Hao Zeng
Journal:  Asian J Androl       Date:  2017 Sep-Oct       Impact factor: 3.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.